THIS ROUND, up to $6M
Min: $100k
Heading to mass production, secure FDA approval & sales.
Our scanner is an innovative imaging system for detecting skin and lesion deformities in cosmetics and skin cancer.
First Prize Winner- Shark Tank
First Prize Winner
Vision-Element
First prize by Vision-Element.com
We collaborate in order to develop an innovative Artificial intelligence (AI) for PatScope's Pattern Recognition.
Chair Capital: Valuation Anchor & Principal Investor
Patternox has entered into an engagement with Chair Capital, a private investment firm acting as Valuation Anchor and Investor. Chair Capital's commitment establishes a defined institutional valuation reference and milestone framework against which interim and co-investment participation can be priced, de-risking participation for incoming investors. As part of its investment architecture, Chair Capital has confirmed its intention to retire loan notes and equity instruments raised during the interim financing process at the point of its principal investment entry, subject to achieving a target IRR, providing early-stage investors with a clear and defined exit pathway. This structure removes the open-ended exit uncertainty that typically increases the cost of early-stage capital, and positions Patternox current fundraise as a time-defined opportunity to invest ahead of an institutional anchor commitment.
How is our system different from other phone based skin/lesion systems?
Patternox differentiates itself from competitors through its core imaging technology, its approach to risk prioritization, and its dual-market accessibility:
-
Subsurface Structural Imaging vs. Visual Pigmentation: While competitors like Skin Analytics (DERM) rely on computer vision to analyze visual color changes, Patternox's patented PatScope uses Shadow Gradient Pattern Imaging (SGPI) and the Lateral Movement of Backscattered Light (LMBI): Instead of looking for pigment contrast, PatScope goes "beyond color" by measuring how light bounces off the physical architecture of the skin to reveal invisible subsurface distortions and tissue abnormalities. Patented in 2026. Innovative concept!
-
Earliest Detection of Colorless Cancers: Because PatScope maps physical volume irregularities rather than pigment, it can identify deformities long before a lesion exhibits visible color changes or physical symptoms. This makes it highly effective at detecting amelanotic (colorless) cancers that standard cameras miss.
-
The "Distortion Score" for Prioritization: Competing devices like DermaSensor and Nevisense typically provide a basic binary output (e.g., "High/Low Risk" or "Biopsy/No Biopsy"). PatScope, utilizing its proprietary AI, maps the surrounding tissue and provides a quantifiable "Distortion Score" (not by color). This explicitly explains why a lesion is suspicious and allows physicians to prioritize which lesions require urgent removal based on mechanical risk.
-
Dual B2B/B2C Architecture: While most diagnostic competitors focus strictly on primary care or specialized dermatology clinics, Patternox has developed a dual-device model.
-
It offers the PatScope-Pro for institutional clinical workflows and the accessible PatScope for home users, medical spas, and estheticians, fully supported by a tele-dermatology infrastructure.